Best Neurology Companies in Germany
The 82 best Neurology companies in Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ATAI.
- Neurology Market Expected to Witness Sustained Growth
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Germany
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ATAI 🦄 Biopharmaceutical company accelerating the development of mental health treatments | $387M | 63 mo ago | 119 | Lars Christian Wilde Co-Founder | — | — | — | — |
| 2 | Vivoryon Developer of therapeutic agents for age related disorders 45Funding top 19%News top 29%Growth top 47%Market top 49% All 7 signals ▾Fundingtop 19% Newstop 29% Growthtop 47% Markettop 49% Talentbottom 49% Globalbottom 39% Techbottom 29% Funding: Raised $112M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) News: 4 BI events in 12 mo (of 6 tracked, 3 types) · Top themes: Earnings, Funding rank vs industry peers · Fliar Intelligence Index 45/100 | $112M | 8 mo ago | 100 | Ulrich Dauer CEO | WordPressMySQLPHP+13 | Top 10M | — | — |
| 3 | Probiodrug Developing new therapeutic products for the treatment of Alzheimer’s disease | $87M | 86 mo ago | — | Konrad Glund Co-Founder & CEO | — | — | 581 patents Development of heterocyclic enzyme inhibitors and humanized therapeutic antibodies for pharmaceuticals. | — |
| 4 | veriNOS pharmaceuticals Developer of therapeutics for retina and brain diseases | $63M | 83 mo ago | 5 | Christian Wandersee CEO | — | — | — | — |
| 5 | Sapiens Neuro Developer of brain stimulation device to treat neurodegenerative disorders | $56M | 150 mo ago | 59 | Sjaak Deckers ex-CEO | — | — | — | — |
| 6 | Protembis Manufacturer of cerebral protection device 29Moat top 25%Innovation top 32%Funding top 32%Patents top 35% All 7 signals ▾Moattop 25% Innovationtop 32% Fundingtop 32% Patentstop 35% Globalbottom 42% Newsbottom 21% Marketbottom 18% Moat: Editorial + unicorn rating 7/10 · IP moat: 59 patents Innovation: 59 patents (top 43% of patent-holders) · 34 filings since 2022 vs 22 in 2017-21 rank vs industry peers · Fliar Intelligence Index 29/100 | $42M | 22 mo ago | 3 | — | — | — | 59 patents Aortic arch embolic protection devices and delivery systems for cardiovascular interventions | — |
| 7 | HMNC Brain Health Developer of targeted therapies for depression and other neuropsychiatric disorders | $41M | 44 mo ago | 18 | — | Apple iCloud MailMicrosoft 365PHP+5 | Top 50M | — | — |
| 8 | Affectis Developer of drugs for the treatment of neurodegenerative and neuroinflammatory diseases | $25M | 195 mo ago | — | Herbert Stadler Founder | — | — | — | — |
| 9 | CorTec Manufacturer of active implantable neurotechnology devices, components, and sub-assemblies | $22M | 40 mo ago | 68 68 → 90 (+32%) | Martin Schuettler Co-Founder | WordPressMySQLPHP+19 | Top 10M | 148 patents Implantable neural interfaces with hermetic, impact‑protected packaging and adaptive stimulation | 1 launch |
| 10 | NeuroCare Group Provider of noninvasive neurotechnology and personalized mental healthcare platform 48Tech top 29%Growth top 37%Moat top 39%Funding top 40% All 10 signals ▾Techtop 29% Growthtop 37% Moattop 39% Fundingtop 40% Patentstop 44% Talentbottom 49% Innovationbottom 48% Globalbottom 39% Marketbottom 34% Newsbottom 18% Tech: 48 technologies across 5/8 capability areas · Cloud: Cloudflare Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $17M | 16 mo ago | 14 | Thomas Mechtersheimer Founder & CEO | Cart FunctionalityWooCommerceWordPress+28 | Top 5M | 9 patents Adaptive transcranial neurostimulation systems with real‑time physiological feedback integration | 1 partnership |
| 11 | MODAG Developer of therapeutics and diagnostics for neurodegenerative diseases 32Moat top 25%Patents top 34%Funding top 40%Innovation top 42% All 7 signals ▾Moattop 25% Patentstop 34% Fundingtop 40% Innovationtop 42% Talentbottom 49% Globalbottom 40% Marketbottom 30% Moat: Editorial + unicorn rating 7/10 · IP moat: 27 patents Patents: 27 patents matched (strict assignee match) · 25 filings since 2022 vs 2 in 2017-21 rank vs industry peers · Fliar Intelligence Index 32/100 | $16M | 6 mo ago | 12 | Torsten Matthias CEO | — | — | 27 patents Patents concentrated in chemistry & materials | — |
| 12 | Algiax Speciality company that develops new products for nervous system diseases with focus on neuropathic pain | $12M | 78 mo ago | 4 | Guido Koopmans Co-Founder & CSO | — | — | — | — |
| 13 | KeyNeurotek Pharmaceuticals Develops drugs for degenerative disorders and autoimmune diseases | $11M | 206 mo ago | — | Frank Striggow CEO | — | — | 14 patents Inhibitors of DPP‑IV and Aminopeptidase N for treating and preventing neurodegeneration | — |
| 14 | Neuway Pharma Therapies for the treatment of brain diseases using its proprietary CNS drug delivery platform | $7M | 120 mo ago | 18 | — | — | — | 33 patents Virus-like particle platforms for mRNA and protein therapeutic delivery | — |
| 15 | BioCrea CNS-focused drug development company with a proprietary compound library & patient-derived IPSC (induced… | $7M | 187 mo ago | — | Tom Kronbach CEO | — | — | 4 patents Novel heterocyclic pharmacophores for anticonvulsant agents and phosphodiesterase inhibitors | — |
| 16 | PROSION Developer of precision medicine technology for cancer treatment | $6M | 50 mo ago | 10 | Mutlu Yonel Co-Founder | WebflowApple iCloud MailMicrosoft 365+9 | Top 50M | — | — |
| 17 | Pantherna Therapeutics Developer of lipid nanoparticle technologies for mRNA-based therapeutics delivery | $4M | 83 mo ago | 12 | Klaus Giese CEO | — | — | 49 patents Lipid nanoparticle delivery systems for nucleic acid‑based therapeutics and vaccines. | — |
| 18 | Nuuron Developer of a digital drug to treat Alzheimer's disease | $4M | 19 mo ago | — | Fabian Queisner Co-Founder & CEO | — | — | 5 patents Non‑invasive high‑frequency brain stimulation devices for neural oscillation modulation | — |
| 19 | Precisis Portfolio of devices and tools for neurological surgery | $3M | 48 mo ago | 14 | — | WordPress Site EditorWordPressMySQL+14 | Top 50M | 82 patents Implantable neurostimulation electrodes and lead connectors for seizure and neural therapy | — |
| 20 | Bomedus Develops products to relieve acute and chronic pain | $3M | 126 mo ago | 11 | Tobias Weigl CEO | — | — | 2 patents Pain‑relief electrotherapy electrode assemblies for neuromodulation devices | — |
| 21 | CerboMed A medical device company which engages in developing neuro therapy solutions. | $3M | 165 mo ago | 5 | — | — | — | 210 patents Implantable and transcutaneous neural stimulation devices with advanced electrode array designs | — |
| 22 | Evanium Developer of selective alcohol antagonist 10Talent top 28%Funding bottom 46%Global bottom 29%Tech bottom 24% All 5 signals ▾Talenttop 28% Fundingbottom 46% Globalbottom 29% Techbottom 24% Marketbottom 20% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $2.6M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 10/100 | $3M | 2 mo ago | 5 | David Ofner Co-Founder | WordPressMySQLPHP+17 | Top 10M | — | 1 launch · 1 award |
| 23 | brainjo AI based plafrom providing cognitive training 21AI top 35%Funding top 44%Talent bottom 49%Product bottom 45% All 7 signals ▾AItop 35% Fundingtop 44% Talentbottom 49% Productbottom 45% Globalbottom 32% Techbottom 31% Marketbottom 22% AI: Product described with: ai based, ai-based Funding: Raised $2.4M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $2M | 2 mo ago | — | Christian Gnerlich Founder | MyWebsiteDudaMyWebsite Creator+10 | Top 10M | — | — |
| 24 | PAM Theragnostics Developer of therapeutic and diagnostic tools for neurodegenerative disorders | $2M | 53 mo ago | — | Andreas Bergmann Founder & CEO | — | — | 26 patents Predictive biomarkers and therapeutic antibodies for immune cell therapy adverse events, plus PAM enzyme diagnostics. | — |
| 25 | Hasomed A portfolio of neurorehabilitation devices | $610K | 113 mo ago | 92 | — | WordPressMySQLPHP+21 | Top 5M | — | 1 partnership |
| 26 | Insellar Developer of minimally invasive brain interfaces for mental health treatment 32Talent top 38%Funding top 49%Global bottom 33% All 3 signals ▾Talenttop 38% Fundingtop 49% Globalbottom 33% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $469k across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $469K | 2 mo ago | — | Selina Greuel Co-Founder & CCO | — | — | — | — |
| 27 | CogniScent Provider of AI-based platform for early detection of neurodegenerative diseases | $355K | 72 mo ago | 2 | Micol Ruvo Co-Founder & CTO | — | — | — | — |
| 28 | Nocturne Provider of medical image analysis platform | $271K | 48 mo ago | 3 | Ella Kadas Managing Director | — | — | 4 patents Retinal optical coherence tomography (OCT) image quality assessment and control | — |
| 29 | Localite Developer of surgical navigation and planning systems | $123K | 44 mo ago | 15 15 → 17 (+13%) | Arno Schmitgen Managing Director | WordPressMySQLPHP+19 | Top 50M | — | — |
| 30 | Sonovum Non-invasive diagnostics of brain disorders using ultrasound | $110K | 127 mo ago | 29 29 → 22 (-24%) | Miroslaw Wrobel Co-Founder & CEO | — | — | 62 patents Wearable acoustic and force sensors for non‑invasive brain pressure and compliance monitoring | — |
Top 12 Neurology companies in Germany
#1
Public · Halle, Saxony Anhalt · founded 1997 · 100 employees$112.2Mraised▾
Vivoryon Therapeutics is developing therapeutic agents for treating age-related diseases. The company leading candidate is PQ912 is in phase 2a of the clinical trial and is for Alzheimer's disease and Cancer, other candidates of the company are PQxxx and PQ1565 which is in the preclinical stage and effective against cancer and other diseases. Theses are small molecule-based and inhibit QTCPL. The company has developed glutaminyl cyclase enzyme inhibitors which is a key enzyme in Alzheimer’s disease and cancer.
- Oct 2025Post IPO$6M
- May 2023Post IPO$26.8M
- Oct 2019Post IPO$47.8M
- Oct 2016Post IPO$16.7M
#2
Series A · Wendelsheim, Rhineland Palatinate · founded 2013 · 12 employees$16.3Mraised▾
Developer of therapeutics and diagnostics for neurodegenerative diseases. The company focuses on research and development of disease-modifying treatments. It offers diagnostic procedures for early detection of neurodegenerative conditions. The company’s research includes oligomer modulators and clinical studies.
- Dec 2025Grant (prize money)$1M
- Jun 2019Series A$16.3M
#3
Seed · Regensburg, Bavaria · founded 2017 · 5 employees$2.6Mraised▾
Evanium is developing a selective alcohol antagonist. The company is developing the therapeutics which is a negative modulator of the GABAA receptor and can antagonize the effect of alcohol on the central nervous system antagonizes the effect of alcohol on the central nervous system.
- Apr 2026Seed$2.6M
#4
Seed · Regensburg, Bavaria · founded 2019$2.4Mraised▾
Brainjo is an AI-based platform that provides cognitive training. The company tests the physical and cognitive performance of the individual and set personal goals. It creates a personal training plan for physical-mental training. It provides training like reaction training, neurofeedback, and brain jogging.
- Apr 2026Seed$2.4M
#5
Seed · Germany · founded 2025$468.7Kraised▾
Developer of minimally invasive brain interfaces for mental health treatment. These devices utilize physiological mechanisms to address major depressive disorder. The technology integrates with biological systems to modulate neural activity for therapeutic purposes.
- Apr 2026Seed$468.7K
#6
Series B · Munich, Bavaria · founded 2015 · 14 employees$17Mraised▾
Provider of noninvasive neurotechnology and personalized mental healthcare platform. The organization develops and supplies digital therapy systems combined with clinical protocols and training for transcranial magnetic stimulation, neurofeedback, EEG, and related neurological assessment tools. It offers a software-based best practice platform that supports clinicians in delivering individualized care through integrated devices, digital workflows, and therapy monitoring. The platform is deployed in its own network of clinics and licensed to third-party practices.
- Feb 2025Series B$20M
- Apr 2024Series A$17M
- Sep 2021Seed—
- Grant (prize money)—
#7
Public · Aachen, North Rhine Westphalia · founded 2013 · 3 employees$42.5Mraised▾
Manufacturer of cerebral protection device It produces a cerebral protection device for use during cardiac surgeries involving the left heart to prevent strokes. Their device consists of an implantable filter system that can be introduced into the aortic arch during minimally invasive procedures which prevent the migration of embolic particles into the cerebral vasculature which prevents strokes.
- Jul 2024Venture Debt$21.7M
- Mar 2024Series B$35.2M
- Oct 2018Series A$10M
- Jul 2015Seed—
#8
Seed · Berlin, Berlin · founded 2023$3.8Mraised▾
Developer of a digital drug to treat Alzheimer's disease. It offers Memory-Pacemaker a non-invasive, photonic neurostimulation to re-enable patients with Alzheimer's Disease to store and recall memories again.
- Oct 2024Seed$3.8M
#9
ATAI 🦄Public · Munich, Bavaria · founded 2018 · 119 employees$386.7Mraised▾
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
#10
Series B · Munich, Bavaria · founded 2010 · 18 employees$41.5Mraised▾
Developer of targeted therapies for depression and other neuropsychiatric disorders. The company has machine learning-based tests to personalize the treatment of neuropsychiatric complications which include depression, stress, and sleep disorders.
- Oct 2022Series B$14M
- Jul 2021Series A$10.6M
#11
Series C · Freiburg im Breisgau, Baden Wurttemberg · founded 2010 · 68 employees$21.6Mraised▾
Manufacturer of active implantable neurotechnology devices, components, and sub-assemblies. They offer design, development, and manufacturing services for medical devices. The company provides cuff electrodes, grid electrodes, paddle and strip electrodes, and percutaneous electrodes. Services include electronics and software development, prototyping, testing, and validation. The Brain Interchange System is available for pre-clinical and clinical research.
- Feb 2023Grant (prize money)—
- 2022Series C—
- Nov 2019Series C$14.4M
- Jun 2016Series B—
#12
Public · Halle, Saxony Anhalt · founded 1997$86.9Mraised▾
Probiodrug is a privately held biopharmaceutical company focused on the development of innovative small molecule drugs. The company is developing inhibitors and ligands targeting key enzymes such as proteases and kinases. The most promising compounds are then developed by Probiodrug as drug candidates for the treatment of major diseases such as Alzheimer's disease or chronic inflammatory disorders. The Company has a dominant position in the area of glutaminyl cyclase inhibition. Glutaminyl cyclase, a novel enzyme target discovered and patented by Probiodrug, has a crucial role in the pathogenesis of Alzheimer's disease (AD) as well as various peripheral inflammatory diseases. Probiodrug is developing drug candidates to specifically target toxic pyroglutamate-Abeta (pGlu-Abeta) via two complementary modes of action: (i) inhibition of Glutaminyl Cyclase (QC), thus inhibiting the production of pGlu-Abeta; and (ii) clearing existing pGlu-Abeta from the brain.
- Apr 2019Post IPO$9.2M
- May 2015Post IPO$19.4M
- Jan 2012Series D$19.5M
- Nov 2009Series C$54M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Neuroscience & Neurotech is moving in Germany
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 2,264 Germany-affiliated papers.
- Charité - Universitätsmedizin Berlin382
- Heinrich Heine University Düsseldorf158
- University Hospital Cologne116
- Medizinische Hochschule Hannover115
- German Center for Neurodegenerative Diseases110
- Deep brain stimulation35→90
- Stimulation29→54
- Brain stimulation5→20
- Neuroprosthetics10→25
- Neuromodulation4→15
- Deep brain stimulation251→348
- Parkinson's disease67→128
- Stimulation123→174
- Brain stimulation13→51
- Subthalamic nucleus120→155
- Brain stimulation10→29
- Disease6→25
- Stimulation34→51
- Deep brain stimulation133→147
- Neuromodulation6→17
Where neurotech is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing neurotech patents in Germany
Germany neurotech patent filing is accelerating — 203 filings from 43 assignees (2016–2025), led by Forschungszentrum Juelich, Brainlab, Biotronik SE & KG; annual filings 29→31.
- Forschungszentrum Juelich94
- Brainlab30
- Biotronik SE & KG22
- Cortec14
- Precisis12
- Braun Melsungen9
- Pajunk Medizintechnologie8
- UNIV Freiburg Albert Ludwigs6
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.